Françoise Muller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Françoise Muller has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Sophie Dreux
Biochemistry-Hormonology, Robert Debré Hospital, AP-HP, Paris, France
4 shared publicationsJean‐François Oury
Obstetrics and Gynecology, Robert Debré Hospital, AP-HP, Paris, France
3 shared publications- Jonathan Rosenblatt
Unité de Médecine Foetale, DMU Gynécologie Périnatalité, APHP, Hôpital Robert Debré, Paris, France
3 shared publications - Emmanuel Spaggiari
Department of Obstetrics and Maternal-Fetal Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris, France
2 shared publications Laurent J. Salomon
Department of Obstetrics and Maternal-Fetal Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris, France
2 shared publicationsRomain Favre
Obstetrics and Gynecology, Hautepierre and CMCO Hospital, Strasbourg, France
2 shared publications
Latest Publications
- 12 September 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (12) , 964-970
Urine biochemistry to predict long‐term outcomes in fetuses with posterior urethral valves
Objective Because the literature on the predictive value of fetal urinalysis is controversial in fetuses with lower urinary tract obstruction, we determined the best model of fetal urine biochemical markers correlated with long‐term postnatal renal function based on glomerular filtration rate (GFR). Method This retrospective study concerned 89 fetuses with lower urinary tract obstruction and their renal function after 10 years of age. We correlated fetal urine biochemical markers (total protein, β2‐microglobulin, sodium, chloride, glucose, calcium, and phosphorus) with GFR at 10 to 30 years of age in 89 patients with posterior urethral valves. We defined five stages of chronic kidney disease (CKD). Results Of the 89 patients, 18 (20%) are 20 years old or over. Postnatal renal function was good in 67.4% (GFR > 60 mL/min/1.73 m2) and poor in 17% (GFR < 30 mL/min/1.73 m2). All fetal urine markers differed between CKD stage 1 + 2 and CKD stage 4 + 5 (P < 0.001). β2‐microblobulin showed an 87% sensitivity for a 72% specificity. A combination of β2‐microglobulin and chloride gave the best results (93% sensitivity and 71% specificity) versus amniotic fluid volume (80% sensitivity and 73% specificity). Conclusion Fetal urine biochemistry predicts long‐term (10‐30 years) postnatal renal function.
- 12 September 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (12) , 964-970
Urine biochemistry to predict long‐term outcomes in fetuses with posterior urethral valves
Objective Because the literature on the predictive value of fetal urinalysis is controversial in fetuses with lower urinary tract obstruction, we determined the best model of fetal urine biochemical markers correlated with long‐term postnatal renal function based on glomerular filtration rate (GFR). Method This retrospective study concerned 89 fetuses with lower urinary tract obstruction and their renal function after 10 years of age. We correlated fetal urine biochemical markers (total protein, β2‐microglobulin, sodium, chloride, glucose, calcium, and phosphorus) with GFR at 10 to 30 years of age in 89 patients with posterior urethral valves. We defined five stages of chronic kidney disease (CKD). Results Of the 89 patients, 18 (20%) are 20 years old or over. Postnatal renal function was good in 67.4% (GFR > 60 mL/min/1.73 m2) and poor in 17% (GFR < 30 mL/min/1.73 m2). All fetal urine markers differed between CKD stage 1 + 2 and CKD stage 4 + 5 (P < 0.001). β2‐microblobulin showed an 87% sensitivity for a 72% specificity. A combination of β2‐microglobulin and chloride gave the best results (93% sensitivity and 71% specificity) versus amniotic fluid volume (80% sensitivity and 73% specificity). Conclusion Fetal urine biochemistry predicts long‐term (10‐30 years) postnatal renal function.
- 12 May 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 585-590
Prenatal diagnosis of megacystis microcolon intestinal hypoperistalsis syndrome by biochemical analysis of fetal urine
Objectives: The objective of the study is to determine a model of fetal urine biochemical markers to differentiate megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) from other megacystis.Method: This is a retrospective study of biochemical analysis of fetal urine in patients who presented prenatally with megacystis. We studied β2‐microglobulin, sodium, calcium, and phosphorus. Twenty‐six patients subsequently diagnosed with MMIHS were compared with 2 control groups: one of end‐stage renal failure (64 fetuses) and the second of “good” postnatal renal function (control group, 64 fetuses).Results: Mean fetal urine β2‐microglobulin was significantly higher (P < .001) in end‐stage renal failure (15.7 mg/L) than in MMIHS (2.2 mg/L) and the control group (3.2 mg/L). Fetal urine profiles differed significantly (P < .001) between MMIHS and the control group: median sodium 46.5 and 51 mmol/L, median calcium 1.12 and 0.73 mmol/L, and median phosphorus 0.03 and 0.15 mmol/L respectively. Fetal urinary ionic index [ratio: calcium / (phosphorus × sodium)] gave an area under the ROC curve of 0.86, at 54% sensitivity and 97% specificity, with correct classification in 84% of cases. We defined a nomogram to obtain a probability for MMIHS.Conclusion: Fetal urinalysis can be helpful in prenatal differentiation of MMIHS from posterior urethral valves with good postnatal renal function.
- 12 May 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 585-590
Prenatal diagnosis of megacystis microcolon intestinal hypoperistalsis syndrome by biochemical analysis of fetal urine
Objectives: The objective of the study is to determine a model of fetal urine biochemical markers to differentiate megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) from other megacystis.Method: This is a retrospective study of biochemical analysis of fetal urine in patients who presented prenatally with megacystis. We studied β2‐microglobulin, sodium, calcium, and phosphorus. Twenty‐six patients subsequently diagnosed with MMIHS were compared with 2 control groups: one of end‐stage renal failure (64 fetuses) and the second of “good” postnatal renal function (control group, 64 fetuses).Results: Mean fetal urine β2‐microglobulin was significantly higher (P < .001) in end‐stage renal failure (15.7 mg/L) than in MMIHS (2.2 mg/L) and the control group (3.2 mg/L). Fetal urine profiles differed significantly (P < .001) between MMIHS and the control group: median sodium 46.5 and 51 mmol/L, median calcium 1.12 and 0.73 mmol/L, and median phosphorus 0.03 and 0.15 mmol/L respectively. Fetal urinary ionic index [ratio: calcium / (phosphorus × sodium)] gave an area under the ROC curve of 0.86, at 54% sensitivity and 97% specificity, with correct classification in 84% of cases. We defined a nomogram to obtain a probability for MMIHS.Conclusion: Fetal urinalysis can be helpful in prenatal differentiation of MMIHS from posterior urethral valves with good postnatal renal function.
- 12 April 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 555-560
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction
Objectives: To compare the prognostic value of fetal serum biochemistry and fetal urine biochemistry in predicting renal outcome in lower urinary tract obstruction (LUTO).Methods: We retrospectively studied renal outcome following a prenatal diagnosis of LUTO in cases for which both fetal blood and fetal urine were sampled. We classified the renal outcome as either “favorable,” when postnatal renal function was normal, or “adverse,” in the case of postnatal chronic renal failure or when renal histological lesions were present at autopsy in the case of termination of pregnancy. A prognostic model was constructed for urine and serum separately. β2‐Microglobulin was the only remaining independent predictor in fetal urine. β2‐Microglobulin in serum and urine were compared by using receiver operating characteristic curves.Results: In the 50 cases included, the rate of adverse outcome was 34 of 50(68%): autopsy confirmed severity of renal disease in all 27 cases who underwent termination of pregnancy, and among the 23 live born children, 7 developed renal failure. Fetal serum and urine markers were all significantly associated with renal outcome (P < .01). The receiver operating characteristic curves for fetal serum and fetal urinary β2‐microglobulin were similar (area under the curve = 0.908 versus 0.909, P = .96).Conclusion: Fetal serum biochemistry and fetal urine biochemistry are of similar prognostic value in predicting postnatal renal outcome in fetuses with LUTO.
- 12 April 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 555-560
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction
Objectives: To compare the prognostic value of fetal serum biochemistry and fetal urine biochemistry in predicting renal outcome in lower urinary tract obstruction (LUTO).Methods: We retrospectively studied renal outcome following a prenatal diagnosis of LUTO in cases for which both fetal blood and fetal urine were sampled. We classified the renal outcome as either “favorable,” when postnatal renal function was normal, or “adverse,” in the case of postnatal chronic renal failure or when renal histological lesions were present at autopsy in the case of termination of pregnancy. A prognostic model was constructed for urine and serum separately. β2‐Microglobulin was the only remaining independent predictor in fetal urine. β2‐Microglobulin in serum and urine were compared by using receiver operating characteristic curves.Results: In the 50 cases included, the rate of adverse outcome was 34 of 50(68%): autopsy confirmed severity of renal disease in all 27 cases who underwent termination of pregnancy, and among the 23 live born children, 7 developed renal failure. Fetal serum and urine markers were all significantly associated with renal outcome (P < .01). The receiver operating characteristic curves for fetal serum and fetal urinary β2‐microglobulin were similar (area under the curve = 0.908 versus 0.909, P = .96).Conclusion: Fetal serum biochemistry and fetal urine biochemistry are of similar prognostic value in predicting postnatal renal outcome in fetuses with LUTO.
- 12 December 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (2) , 106-109
Impact of a shift in nuchal translucency measurements on the detection rate of first‐trimester Down syndrome screening: A population‐based study
Objective: To assess the distribution of nuchal translucency (NT) measurements following a national policy without credentialing and its impact on first‐trimester Down syndrome screening (DSS) detection rate.Method: All first‐trimester DSS data recorded in France (2010‐2014) were collected by the laboratories in charge via an Internet database (https://www.bionuqual.org/echo.php). There was no minimal requirement for image quality to allow sonographers to enter the screening process. A subgroup of DSS with complete DS follow‐up corresponded to 1614 sonographers. Based on the distribution of maternal age, DS detection rate was calculated and split as a function of the distribution of NT multiple of the median (MoM).Results: Four thousand nine hundred forty‐three sonographers performed 2,337,372 NT measurements. Median NT expressed in MoM was 0.83. Screenings with complete follow‐up consisted of 197,417 screenings, in which DSS detection rates were respectively 70.4%, 70.9%, 79.4%, 87.7%, and 79.5% for the following median NT MoM ranges: 0.99 (trend χ = 12.21; P = .0158).Conclusion: In France, following a policy of quality assessment without standardized credentialing, the distribution of NT measurements did not fit the expected distribution. Down syndrome detection rate was 10% lower in screenings by sonographers with a median NT < 0.80 MoM.
- 12 December 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (2) , 106-109
Impact of a shift in nuchal translucency measurements on the detection rate of first‐trimester Down syndrome screening: A population‐based study
Objective: To assess the distribution of nuchal translucency (NT) measurements following a national policy without credentialing and its impact on first‐trimester Down syndrome screening (DSS) detection rate.Method: All first‐trimester DSS data recorded in France (2010‐2014) were collected by the laboratories in charge via an Internet database (https://www.bionuqual.org/echo.php). There was no minimal requirement for image quality to allow sonographers to enter the screening process. A subgroup of DSS with complete DS follow‐up corresponded to 1614 sonographers. Based on the distribution of maternal age, DS detection rate was calculated and split as a function of the distribution of NT multiple of the median (MoM).Results: Four thousand nine hundred forty‐three sonographers performed 2,337,372 NT measurements. Median NT expressed in MoM was 0.83. Screenings with complete follow‐up consisted of 197,417 screenings, in which DSS detection rates were respectively 70.4%, 70.9%, 79.4%, 87.7%, and 79.5% for the following median NT MoM ranges: 0.99 (trend χ = 12.21; P = .0158).Conclusion: In France, following a policy of quality assessment without standardized credentialing, the distribution of NT measurements did not fit the expected distribution. Down syndrome detection rate was 10% lower in screenings by sonographers with a median NT < 0.80 MoM.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- 20 July 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 289 (2) , 461-462
Use of insulin-like growth factor binding protein-1 for retrospective diagnosis of amniotic fluid embolism in first trimester
- 20 July 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 289 (2) , 461-462
Use of insulin-like growth factor binding protein-1 for retrospective diagnosis of amniotic fluid embolism in first trimester
- 1 October 2009
- Published by Elsevier in Immuno-analyse & Biologie Spécialisée
- Vol. 24 (5-6) , 235-239
Dépistage prénatal de la trisomie 21 : les nouvelles recommandations
- 1 October 2009
- Published by Elsevier in Immuno-analyse & Biologie Spécialisée
- Vol. 24 (5-6) , 235-239
Dépistage prénatal de la trisomie 21 : les nouvelles recommandations
- 1 March 2000
- Published by Springer Nature in Human Genetics
- Vol. 106 (3) , 340-344
Parental origin of the extra chromosome in prenatally diagnosed fetal trisomy 21
- 1 March 2000
- Published by Springer Nature in Human Genetics
- Vol. 106 (3) , 340-344
Parental origin of the extra chromosome in prenatally diagnosed fetal trisomy 21
- 18 August 1999
- Published by Wiley in Prenatal Diagnosis
- Vol. 19 (8) , 755-757
Correlation of alkaline phosphatase (ALP) determination and analysis of the tissue non‐specific ALP gene in prenatal diagnosis of severe hypophosphatasia
Prenatal diagnosis of severe hypophosphatasia by mutation analysis of the tissue non-specific alkaline phosphatase (TNSALP) gene is reliable and mostly informative. However, alkaline phosphatase (ALP) assay of CVS may be a useful complementary and independent method, especially when a mutation is unidentified and DNA from the index case is unavailable, rendering impossible the use of DNA polymorphisms as genetic markers of the disease. We report here mutation analysis of the TNSALP gene and ALP assay in nine cases of prenatal diagnosis of severe hypophosphatasia. The results showed a good correlation between ALP assay and DNA analysis in all but one case, which suggested that in at least some cases low values of ALP may correspond to affected fetuses as well as to heterozygotes.
- 18 August 1999
- Published by Wiley in Prenatal Diagnosis
- Vol. 19 (8) , 755-757
Correlation of alkaline phosphatase (ALP) determination and analysis of the tissue non‐specific ALP gene in prenatal diagnosis of severe hypophosphatasia
Prenatal diagnosis of severe hypophosphatasia by mutation analysis of the tissue non-specific alkaline phosphatase (TNSALP) gene is reliable and mostly informative. However, alkaline phosphatase (ALP) assay of CVS may be a useful complementary and independent method, especially when a mutation is unidentified and DNA from the index case is unavailable, rendering impossible the use of DNA polymorphisms as genetic markers of the disease. We report here mutation analysis of the TNSALP gene and ALP assay in nine cases of prenatal diagnosis of severe hypophosphatasia. The results showed a good correlation between ALP assay and DNA analysis in all but one case, which suggested that in at least some cases low values of ALP may correspond to affected fetuses as well as to heterozygotes.
- 1 July 1994
- Published by Wiley in Prenatal Diagnosis
- Vol. 14 (7) , 633-636
Do racial differences exist in second-trimester maternal hCG levels? a study of 23 369 patients
In Down syndrome screening by maternal serum human chorionic gonadotropin (hCG) determination at 15, 16, 17, and 18 weeks of gestation, we prospectively examined 23 369 sera from white (21 549), North African (970), black African (525), and Asian (325) patients. When expressed as multiples of the median (MOM), no difference was observed between white, North African, and black African patients. However, higher serum hCG concentrations were noted in Asians, for whom we therefore recommend correction of hCG values before calculation of the risk of Down syndrome.
- 1 July 1994
- Published by Wiley in Prenatal Diagnosis
- Vol. 14 (7) , 633-636
Do racial differences exist in second-trimester maternal hCG levels? a study of 23 369 patients
In Down syndrome screening by maternal serum human chorionic gonadotropin (hCG) determination at 15, 16, 17, and 18 weeks of gestation, we prospectively examined 23 369 sera from white (21 549), North African (970), black African (525), and Asian (325) patients. When expressed as multiples of the median (MOM), no difference was observed between white, North African, and black African patients. However, higher serum hCG concentrations were noted in Asians, for whom we therefore recommend correction of hCG values before calculation of the risk of Down syndrome.